AVALO THERAPEUTICS INC (AVTX)

US05338F3064 - Common Stock

11.28  +0.26 (+2.36%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AVALO THERAPEUTICS INC

NASDAQ:AVTX (6/12/2024, 9:46:50 AM)

11.28

+0.26 (+2.36%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-23.51%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap11.62M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AVTX Daily chart

Company Profile

Avalo Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland and currently employs 20 full-time employees. The company went IPO on 2015-11-13. Avalo Therapeutics, Inc. is a clinical-stage biotechnology company. The firm is focused on the treatment of immune dysregulation by developing therapies that target the Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT)-signaling network. The company is focused on advancing a pipeline that emphasizes high value potential first-in-class biologics focused on dysregulated inflammation through the LIGHT-signaling network. Its pipeline includes AVTX-002, and AVTX-008. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, Crohn’s Disease, and COVID-19 acute respiratory distress syndromes. AVTX-008 is a fully human B and T lymphocyte attenuator (BTLA) agonist fusion protein that is being evaluated for several immune dysregulation disorders.

Company Info

AVALO THERAPEUTICS INC

540 Gaither Rd Ste 400

Rockville MARYLAND

P: 14105228707

CEO: Michael Cola

Employees: 20

Website: https://www.avalotx.com/

AVTX News

News Image19 days ago - InvestorPlaceAVTX Stock Earnings: Avalo Therapeutics Misses EPS, Beats Revenue for Q4 2023

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

News Image19 days ago - BusinessInsiderAVTX Stock Earnings: Avalo Therapeutics Misses EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avalo Therapeutics (NASDAQ:AVTX) just reported results for the fourth quarter o...

News Imagea month ago - InvestorPlaceAVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

News Imagea month ago - BusinessInsiderAVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avalo Therapeutics (NASDAQ:AVTX) just reported results for the first quarter of...

News Imagea month ago - Avalo TherapeuticsAvalo Reports First Quarter 2024 Financial Results and Provides Business Updates
News Imagea month ago - Avalo TherapeuticsAvalo Reports First Quarter 2024 Financial Results and Provides Business Updates

WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024.

AVTX Twits

Here you can normally see the latest stock twits on AVTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example